People: Hemispherx Biopharma Inc (HEB)

HEB on American Stock Exchange

0.22USD
27 Mar 2015
Change (% chg)

$-0.00 (-0.88%)
Prev Close
$0.23
Open
$0.23
Day's High
$0.23
Day's Low
$0.22
Volume
919,612
Avg. Vol
1,906,360
52-wk High
$0.42
52-wk Low
$0.21

Search Stocks

Summary

Name Age Since Current Position

William Carter

77 2006 Chairman of the Board, Chief Executive Officer, Chief Scientific Officer

Thomas Equels

62 2013 Executive Vice Chairman of the Board, Chief Financial Officer, General Counsel, Secretary, Litigation Counsel

Wayne Springate

43 2011 Senior Vice President - Operations

Adam Pascale

2013 Chief Accounting Officer

David Strayer

69 2010 Chief Medical Officer, Medical Director - Regulatory Affairs

Iraj Kiani

69 2013 Lead Independent Director

Peter Rodino

63 2013 Director

William Mitchell

80 1998 Independent Director

Charles Jones

2012 Associates Public Relations

Biographies

Name Description

William Carter

Dr. William A. Carter, M.D., is Chairman of the Board, Chief Executive Officer, Chief Scientific Officer of Hemispherx Biopharma Inc. has served as our Chief Scientific Officer since May 1989 and the Chairman of our Board of Directors since January 1992. He served as Chief Executive Officer since July 1993 and President from April 1995 to November 2006 and Director since 1987. From 1987 to 1988, Dr. Carter served as our Chairman. Dr. Carter was a leading innovator in the development of human interferon for a variety of treatment indications including various viral diseases and cancer. Dr. Carter received the first FDA approval to initiate clinical trials on a beta interferon product manufactured in the U.S. under his supervision. From 1985 to October 1988, Dr. Carter served as our Chief Executive Officer and Chief Scientist. He received his M.D. degree from Duke University and underwent his post-doctoral training at the National Institutes of Health and Johns Hopkins University. Dr. Carter also served as Professor of Neoplastic Diseases at Hahnemann Medical University, a position he held from 1980 to 1998. Dr. Carter served as Professor and Director of Clinical Research for Hahnemann Medical University's Institute for Cancer and Blood Diseases, and as a member of the faculty at Johns Hopkins School of Medicine and the State University of New York at Buffalo. Dr. Carter is a Board certified physician and author of more than 200 scientific articles, including the editing of various textbooks on anti-viral and immune therapy.

Thomas Equels

Mr. Thomas K. Equels Esq., is Executive Vice Chairman of the Board, Chief Financial Officer, General Counsel, Secretary, Litigation Counsel of Hemispherx Biopharma Inc. In addition, since December 2, 2013, when Charles T. Bernhardt resigned (see below for disclosure on Mr. Bernhardt's resignation), Mr. Equels has served as our Chief Financial Officer. Mr. Equels is the President and Managing Director of the Equels Law Firm headquartered in Miami, Florida that focuses on litigation. For over a quarter century, Mr. Equels has represented national and state governments as well as companies in the banking, insurance, aviation, pharmaceutical and construction industries. Mr. Equels received his Juris Doctor degree with high honors from Florida State University. He is a summa cum laude graduate of Troy University and also obtained his Masters' Degree from Troy. He is a member of the Florida Bar Association and the American Bar Association.

Wayne Springate

Mr. Wayne S. Springate is Senior Vice President - Operations of Hemispherx Biopharma Inc. Mr. Springate joined Hemispherx in 2002 as Vice President of Business Development when Hemispherx acquired Alferon N Injection® and its New Brunswick, NJ manufacturing facilities. He led the consolidation of our Rockville facility to our New Brunswick location as well as coordinated the relocation of manufacturing polymers from South Africa to our production facility in New Brunswick. He was also responsible for preparing and having a successful Preapproval Inspection by the FDA for our New Brunswick manufacturing plant in connection with the filing of our Ampligen® NDA. Currently he is managing a capital improvement budget to enhance our Alferon® facility in accordance with cGMP. Previously, Mr. Springate served as President for World Fashion Concepts in New York and oversaw operations at several locations throughout the United States and overseas. Mr. Springate assists the CEO in details of operations on a daily basis and is involved in all aspects of manufacturing, warehouse management, distribution and logistics.

Adam Pascale

Mr. Adam Pascale is Chief Accounting Officer of the company. Mr. Pascale has been the Controller at Hemispherx for eighteen years, with twenty four years of public accounting experience and prior public company experience. His degree is from Rutgers University in Accounting and he served for many years as a CPA prior to joining Hemispherx. He is a member of both the American and the Pennsylvania Institutes of Certified Public Accountants. According to Mr. Equels, "Adam has the education and experience to excel in the function of Chief Accounting Officer. I look forward to working with him to create a stronger, better, Hemispherx."

David Strayer

Dr. David R. Strayer, M.D., is Chief Medical Officer, Medical Director - Regulatory Affairs of Hemispherx Biopharma Inc. He has served as Professor of Medicine at the Medical College of Pennsylvania and Hahnemann University. Dr. Strayer is Board Certified in Medical Oncology and Internal Medicine with research interests in the fields of cancer and immune system disorders. He has served as principal investigator in studies funded by the Leukemia Society of America, the American Cancer Society, and the National Institutes of Health. Dr. Strayer attended the School of Medicine at the University of California at Los Angeles where he received his M.D. in 1972.

Iraj Kiani

Dr. Iraj Eqhbal Kiani, N.D., Ph.D., is Lead Independent Director of Hemispherx Biopharma Inc. Dr. Kiani was appointed to be the Board's Lead Director due to the resignation of Mr. Piani due to health reasons. Dr. Kiani is a citizen of the United States and England and resides in Newport Beach, California. Dr. Kiani served in various local government positions including the Mayor and Governor of Yasoug, Capital of Boyerahmand, Iran. In early 1980, Dr. Kiani moved to England, where he established and managed several trading companies over a period of some 20 years. Dr. Kiani is a planning and logistic specialist who is now applying his knowledge and experience to build a worldwide immunology network. Dr. Kiani received his Ph.D. degree from the University of Ferdosi in Iran, and his ND from American University.

Peter Rodino

Mr. Peter W. Rodino III, Esq., is Director of Hemispherx Biopharma, Inc. Mr. Rodino's appointment was the result of the resignation of Richard C. Piani due to health reasons. Mr. Rodino has broad legal, financial, and executive experience. In addition to being President of Rodino Consulting LLC and managing partner at several law firms during his many years as a practicing attorney, he served as Chairman and CEO of Crossroads Health Plan, the first major Health Maintenance Organization in New Jersey. He also has had experience as an investment executive in the securities industry and acted as trustee in numerous Chapter 11 complex corporate reorganizations. For the past 17 years, as founder and president of Rodino Consulting, Mr. Rodino has provided business and government relations consulting services to smaller companies with a focus on helping them develop business plans, implement marketing strategies and acquire investment capital. Mr. Rodino holds a B.S. in Business Administration from Georgetown University and a J.D. degree from Seton Hall University.

William Mitchell

Dr. William M. Mitchell, M.D., Ph.D., is Independent Director of Hemispherx Biopharma Inc., since July 1998. Dr. Mitchell is a Professor of Pathology at Vanderbilt University School of Medicine and is a board certified physician. Dr. Mitchell earned a M.D. from Vanderbilt and a Ph.D. from Johns Hopkins University, where he served as House Officer in Internal Medicine, followed by a Fellowship at its School of Medicine. Dr. Mitchell has published over 200 papers, reviews and abstracts that relate to viruses, anti-viral drugs, immune responses to HIV infection, and other biomedical topics. Dr. Mitchell has worked for and with many professional societies that have included the American Society of Investigative Pathology, the International Society for Antiviral Research, the American Society of Clinical Oncology, the American Society of Biochemistry and Molecular Biology and the American Society of Microbiology. Dr. Mitchell is a member of the American Medical Association. He has served on numerous government review committees, among them the National Institutes of Health, AIDS and Related Research Review Group. Dr. Mitchell previously served as one of our Directors from 1987 to 1989.

Charles Jones

Basic Compensation

Name Fiscal Year Total

William Carter

2,364,880

Thomas Equels

1,668,450

Wayne Springate

344,164

Adam Pascale

--

David Strayer

367,334

Iraj Kiani

--

Peter Rodino

--

William Mitchell

--

Charles Jones

--
As Of  30 Dec 2014

Options Compensation

Search Stocks